Drugs / FAB117-HC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02917291 | Dec 2016 → Jul 2022 | spinal cord injury | Ferrer Internacional S.A. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAB117-HC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02917291 ↗ |
| Modality | Cell therapy | “allogeneic adipose-derived adult mesenchymal stem cells” NCT02917291 ↗ |
| Route | Other | “Intramedullary administration” NCT02917291 ↗ |